Serengeti Asset Management’s Cardlytics CDLX Stock Holding History

Serengeti Asset Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,500	Closed	-$825K	–	43
2022 Q1	$825K	Buy	+1,500	New	+$907K	1.68%	12
2020 Q4	–	Sell	-6,000	Closed	-$4.23M	–	19
2020 Q3	$4.23M	Sell	6,000 -1,000	-14%	-$727K	1.33%	8
2020 Q2	$4.9M	Buy	+7,000	New	+$4.04M	1.72%	9

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Serengeti Asset Management's CDLX Position: Q2 2022 in Review

Serengeti Asset Management sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 1,500 shares — an estimated $825K sold.

Serengeti Asset Management first reported a position in CDLX in Q2 2020 and held it in 3 quarters. The position peaked at $4.9M in Q2 2020. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.

Serengeti Asset Management reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
Serengeti Asset Management sold 1,500 Cardlytics shares in Q2 2022, an estimated $825K.
Serengeti Asset Management first reported a position in Cardlytics in Q2 2020 and held it in 3 quarters.
Serengeti Asset Management's Cardlytics position peaked at $4.9M in Q2 2020.
138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.

Based on Serengeti Asset Management's 13F filing for Q2 2022, filed 2 Aug 2022.